Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation
Karen Mendelson, … , Ramon E. Parsons, Julide Tok Celebi
Karen Mendelson, … , Ramon E. Parsons, Julide Tok Celebi
Published February 6, 2024
Citation Information: JCI Insight. 2024;9(6):e166611. https://doi.org/10.1172/jci.insight.166611.
View: Text | PDF
Research Article Dermatology

Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation

  • Text
  • PDF
Abstract

Dedifferentiation or phenotype switching refers to the transition from a proliferative to an invasive cellular state. We previously identified a 122-gene epigenetic gene signature that classifies primary melanomas as low versus high risk (denoted as Epgn1 or Epgn3). We found that the transcriptomes of the Epgn1 low-risk and Epgn3 high-risk cells are similar to the proliferative and invasive cellular states, respectively. These signatures were further validated in melanoma tumor samples. Examination of the chromatin landscape revealed differential H3K27 acetylation in the Epgn1 low-risk versus Epgn3 high-risk cell lines that corroborated with a differential super-enhancer and enhancer landscape. Melanocytic lineage genes (MITF, its targets and regulators) were associated with super-enhancers in the Epgn1 low-risk state, whereas invasiveness genes were linked with Epgn3 high-risk status. We identified the ITGA3 gene as marked by a super-enhancer element in the Epgn3 invasive cells. Silencing of ITGA3 enhanced invasiveness in both in vitro and in vivo systems, suggesting it as a negative regulator of invasion. In conclusion, we define chromatin landscape changes associated with Epgn1/Epgn3 and phenotype switching during early steps of melanoma progression that regulate transcriptional reprogramming. This super-enhancer and enhancer-driven epigenetic regulatory mechanism resulting in major changes in the transcriptome could be important in future therapeutic targeting efforts.

Authors

Karen Mendelson, Tiphaine C. Martin, Christie B. Nguyen, Min Hsu, Jia Xu, Claudia Lang, Reinhard Dummer, Yvonne Saenger, Jane L. Messina, Vernon K. Sondak, Garrett Desman, Dan Hasson, Emily Bernstein, Ramon E. Parsons, Julide Tok Celebi

×

Figure 1

Epigenetic gene signature classifier (Epgn1/Epgn3) underlies reprogramming of melanoma cells from a proliferative to an invasive cellular state.

Options: View larger image (or click on image) Download as PowerPoint
Epigenetic gene signature classifier (Epgn1/Epgn3) underlies reprogrammi...
RNA-Seq of Epgn1 cell lines (n = 3; WM35, YUPEET, WM983A) and Epgn3 cell lines (n = 2; WM1552C, YUCHIME). The top bar indicates cellular subtypes (Epgn1 [red] and Epgn3 [light blue]) as characterized by the 122-epigenetic signature (Supplemental Figure 1A). Each row of the heatmap indicates a differentially expressed gene, and each column represents a BRAFV600 mutant cell line (n = 5; each in triplicate). Differentially expressed genes are significant if q < 0.05 by Benjamini-Hochberg procedure and a linear fold-change ± 1.5. The heatmaps are color-coded on the basis of Z scores. (A) Supervised hierarchical clustering of 122 epigenetic genes and identification of Epgn1 and Epgn3 groups. (B) RNA-Seq analysis identifies increased expression of proliferative and differentiation genes (MLANA, TYR, DCT, MITF) in the Epgn1 group and increased expression of invasive genes (WNT5A, ITGA2, ZEB1, EGFR, ITGA3, PDGFC, NRP, AXL) in the Epgn3 group using the Hoek proliferative and invasive gene signature (2). (C) Pigmentation pathway genes (MITF, MLANA, PMEL, TYR, DCT, TYRP1) were uniformly upregulated in Epgn1 cells. (D and E) Differential expression of genes involved in epithelial mesenchymal transition (EMT) and integrin signaling. (F) Heatmap of 51 significantly differentially expressed proteins (after multitesting correction at FDR 5%) determined by reverse phase protein array (RPPA) coincides with transcriptional data. (G) GSEA pathway analysis. Pathways are abbreviated as follows: K, KEGG; R, Reactome; H, Hallmark; P, Pathway Interaction Database. (H) RNA-Seq data set of TCGA melanomas (n = 473). ssGSEA analysis depicting correlation between the upregulated Epng1 gene signature with the proliferative genes (P = 1.069 × 10–6; OR, 2.61), and the upregulated Epgn3 signature with the invasive genes (P = 8.595 × 10–6; OR, 2.46).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts